Can this under-the-radar company cash in on the $150 bn weight-loss drug boom?

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with expanding capacity, strong global clients, and rising revenue from FY26 onwards.

Markets